<!-- page 1 -->

# **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE** 

## **HEALTH TECHNOLOGY APPRAISAL PROGRAMME** 

# **Equality impact assessment – Scoping** 

## **STA Pembrolizumab with chemotherapy for treating HER2 negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]** 

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme. 

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? 

No 

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? 

Not applicable 

3. Has any change to the draft scope been agreed to highlight potential equality issues? 

Not applicable 

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? 

Technology appraisals: Scoping 

Equality impact assessment for the proposed single technology appraisal of Pembrolizumab with chemotherapy for treating HER2 negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID 4030] Issue date: July 2023 

1 of 2 



<!-- page 2 -->

No additional stakeholders identified. 

## **Approved by Associate Director (name):** Janet Robertson 

**Date:** 07 July 2023 

Technology appraisals: Scoping Equality impact assessment for the proposed single technology appraisal of Pembrolizumab with chemotherapy for treating HER2 negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID 4030] Issue date: July 2023 

2 of 2 

